- Revive Therapeutics (RVVTF, Financial) is conducting a study on Bucillamine as a potential countermeasure against nerve agents.
- The research, in collaboration with Defence R&D Canada – Suffield Research Centre, is to continue until September 2025.
- Findings from the study will be disclosed only with the DRDC's authorization.
Revive Therapeutics Ltd. (RVVTF), a specialized life sciences company, has clarified its ongoing efforts in examining the use of Bucillamine as a treatment for exposure to nerve agents. This research is being executed in partnership with Defence R&D Canada – Suffield Research Centre (DRDC), part of the Canadian Department of National Defence.
The study aims to explore Bucillamine along with other pharmacological compounds for their ability to mitigate brain injuries induced by nerve agents. The investigation is set to continue through September 2025, after which results will be released exclusively with the DRDC's express permission.
Revive Therapeutics has emphasized that any further research collaborations with the DRDC will be contemplated only after the current study's conclusion and are subject to satisfactory outcomes. This initiative highlights the company's commitment to developing potential medical countermeasures, leveraging regulatory incentives such as Emergency Use Authorization and Orphan Drug Designation.
